Revuforj (revumenib) PDUFA Date (Syndax Pharmaceuticals)

Name: FDA PDUFA Decision: Revuforj (revumenib)
Start: 2025-10-25

FDA PDUFA decision date for Revuforj (revumenib) is October 25, 2025. Developed by Syndax Pharmaceuticals. Indication: NPM1-mutant acute myeloid leukemia. Current status: Approved.

Indication

NPM1-mutant acute myeloid leukemia

Regulatory details

Company: Syndax Pharmaceuticals
Therapeutic area: Oncology
Application type: sNDA
Review type: Priority
PDUFA date: 2025-10-25
Outcome: Approved

Revuforj (revumenib) PDUFA Date — Syndax Pharmaceuticals